| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.23 | 3e-06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.26 | 5e-06 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.21 | 7e-05 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.15 | 9e-05 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0001 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.2 | 0.0002 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0005 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.0005 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0006 |